Skip to main
KRYS
KRYS logo

Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech (KRYS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 80%
Buy 13%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Krystal Biotech Inc has demonstrated a solid financial performance with net revenue from its product Vyjuvek reaching $91.1 million in the most recent quarter, reflecting a 9% increase from the previous quarter, and total annual revenue of $290.5 million aligning with fiscal year projections. The company's innovative gene therapy platform, STAR-D, has shown promising preclinical data, particularly in improving survival rates for patients with difficult-to-treat conditions, indicating potential for future product development and market expansion. Furthermore, the company's strong financial position, characterized by disciplined operating expense management and the possibility of a share repurchase program, enhances its attractiveness as a growth-at-a-reasonable-price (GARP) investment opportunity.

Bears say

Krystal Biotech's stock outlook is negatively affected by a downward trend in new reimbursement approvals, with projections indicating a decline from 70 in 2Q24 to 50 in 4Q24, which raises concerns about revenue generation. Furthermore, the company faces significant risks related to the complexity and novelty of gene therapy manufacturing, potentially leading to delays in product development and commercialization. Compounding these issues are competitive pressures and challenges in patient recruitment for clinical trials, which may hinder the company's ability to achieve its financial targets.

Krystal Biotech (KRYS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 13% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Krystal Biotech (KRYS) Forecast

Analysts have given Krystal Biotech (KRYS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, Krystal Biotech (KRYS) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Krystal Biotech (KRYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.